- Guide to PHARMACOLOGY
Synonyms: Farydak® | LBH-589 | LBH589
panobinostat is an approved drug (EMA & FDA (2015))
Compound class: Synthetic organic
Comment: Panobinostat is a non-selective histone deacetylase (HDAC) inhibitor [3-4]. The compound also has antimalarial activity.
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: panobinostat
|Guide to Malaria Pharmacology Comments|
|A study examining the antimalarial activity of four clinically approved small molecule HDAC inhibitors, found that panobinostat was the most potent compound in vitro .
Potential Target/Mechanism Of Action: Plasmodium histone deacetylase is the likely molecular target (see our PfHDAC1 target page for more details).